 | • レポートコード：MRC2303I0026 • 出版社/出版日：Mordor Intelligence / 2023年1月23日 • レポート形態：英文、PDF、120ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医療 |
| Single User | ￥712,500 (USD4,750) | ▷ お問い合わせ |
| Corporate License | ￥1,312,500 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Mordor Intelligence社の本調査レポートでは、世界の慢性静脈閉塞症治療市場規模が、予測期間中（2022年〜2027年）に年平均9%で成長すると予測しています。本レポートは、慢性静脈閉塞症治療の世界市場について調べ、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、治療種類別（慢性深部静脈血栓症、静脈閉塞症、深部静脈不全症、その他）分析、製品種類別（装置、治療薬）分析、地域別（アメリカ、カナダ、メキシコ、ドイツ、イギリス、フランス、イタリア、スペイン、中国、日本、インド、オーストラリア、韓国、中東、南アフリカ、ブラジル、アルゼンチン）分析、競争状況、市場機会・将来の動向などを以下の構成でまとめています。また、Cardinal Health、Stryker、Cook Medical、Boston Scientific Corporation、Edward Lifesciences、Angio Dynamics、ENDOCOR、Rontis、Penumbra、BD Advancing the World of Healthなどの企業情報が含まれています。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界の慢性静脈閉塞症治療市場規模：治療種類別 - 慢性深部静脈血栓症における市場規模 - 静脈閉塞症における市場規模 - 深部静脈不全症における市場規模 - その他治療における市場規模 ・世界の慢性静脈閉塞症治療市場規模：製品種類別 - 装置の市場規模 - 治療薬の市場規模 ・世界の慢性静脈閉塞症治療市場規模：地域別 - 北米の慢性静脈閉塞症治療市場規模 アメリカの慢性静脈閉塞症治療市場規模 カナダの慢性静脈閉塞症治療市場規模 メキシコの慢性静脈閉塞症治療市場規模 … - ヨーロッパの慢性静脈閉塞症治療市場規模 ドイツの慢性静脈閉塞症治療市場規模 イギリスの慢性静脈閉塞症治療市場規模 フランスの慢性静脈閉塞症治療市場規模 … - アジア太平洋の慢性静脈閉塞症治療市場規模 中国の慢性静脈閉塞症治療市場規模 日本の慢性静脈閉塞症治療市場規模 インドの慢性静脈閉塞症治療市場規模 … - 中東/南米の慢性静脈閉塞症治療市場規模 南アフリカの慢性静脈閉塞症治療市場規模 ブラジルの慢性静脈閉塞症治療市場規模 アルゼンチンの慢性静脈閉塞症治療市場規模 … - その他地域の慢性静脈閉塞症治療市場規模 ・競争状況 ・市場機会・将来の動向 |
The chronic venous occlusion market is expected to register a CAGR of 9% during the forecast period (2022-2027).
The COVID-19 pandemic has impacted the market. The companies had faced an extreme decline in their operating earnings, sales revenue from the segments, and discontinuation of the procedures. Additionally, the commercial or clinical supply of the medicines and drug candidates has been impacted due to the shutdown of the company’s, or the third-party manufacturing facilities, distribution channels, and transportation systems. For instance, AngioDynamics reported decreased sales in Venous products in 2020. This was due to the termination of elective procedures by the hospitals.
Chronic venous occlusion treatment has a high adoption rate due to the increasing prevalence of chronic venous diseases. According to the National Center for Biotechnology Information, 2021, more than 30 million people have some form of chronic venous disease in the United States. In addition, the prevalence of chronic venous disease is 10 times more than peripheral artery diseases. The factors driving the growth of the venous occlusion treatment market include increasing genetic disorders, the rising geriatric population, and obese and pregnant women who are also prone to chronic venous occlusions. Venous occlusion has been observed in people having bone disorders. According to the National Center for Biotechnology Information, 2021, it has been found that 25% of females and 75% of males having bone disorders have experienced venous occlusion. Additionally, increasing availability of advanced chronic venous occlusion treatments and devices and increasing adoption of minimally invasive procedures involving low risk of infections and minimum hospital stays, thus saving the cost and time, also boost the growth of the market. Also, the increasing adoption of different strategies by companies and manufacturers to expand their product portfolios and to enter the chronic venous occlusion treatment market is likely to boost the growth of the market. For instance, Hancock Jaffe Laboratories announced that the United States Food and Drug Administration (FDA) had granted the Breakthrough Device designation status to the company’s lead product, VenoValve. Moreover, the companies are focusing on developing drug candidates for the treatment of venous insufficiencies, such as P-TEV, TR 987, and Sulodexide.
However, lack of awareness and skilled specialists, risks associated with the procedures, and the high cost of chronic total occlusion treatment are the major factors hindering the growth of the market.
Chronic Venous Occlusions Treatment Market Trends
The Devices Segment is Expected to Drive the Market Growth
The increasing prevalence of cardiovascular diseases and the growing geriatric population are expected to be the key driving factors for the growth of the devices segment during the forecast period. The older population is more likely to develop cardiovascular diseases. According to Ageing Europe Statistics, 2021, it has been observed that more than one-fifth (20.8%) of the European population was aged 65 years and over. In addition, it is projected that the share of people aged 80 years or above in the European population will have a two-and-a-half-fold increase between 2021 and 2100, from 6.0% to 14.6%. For instance, women aged over 40 years who are suffering from varicose veins are usually treated with V-block occluding stent, a self-expandable device that functions as a vein occluder and blood clot trap.
In addition, the rising demand for non-invasive procedures is likely to boost the growth of the market. For instance, cardiac catheterization, a minimally invasive way, is used to diagnose and treat a variety of heart and vascular conditions, such as May-Thurner syndrome, by guiding thin, flexible tubes called catheters through blood vessels to problem areas.
The clinicians advised the implantation of stents in patients suffering from cardiovascular disorders such as blockages in the heart or sudden heart attacks to widen up the narrow veins of the heart to regulate the flow of blood in the heart and body. According to the American Heart Association, 2020, approximately 2 million stents are implanted in the United States every year. Increasing hypertension among masses significantly increases the risk of heart diseases and affects the normal blood flow in the body. According to the statistics published by the World Health Organization, 2021, an estimated 1,28 billion adults aged 30-79 years have heart diseases, and approximately two-thirds of the population live in low- or middle-income countries. According to the European Society of Cardiology, more than 6 million new cases of cardiovascular diseases are found in the European Union and more than 12 million in Europe as a whole every year.
These factors are contributing to the growth of the chronic venous occlusion treatment market during the forecast period.
North America Dominates the Market, and It is Expected to do the Same During the Forecast Period
North America is projected to hold significant shares in the chronic venous occlusion treatment market. This is due to the presence of a number of treatment facilities and advanced healthcare infrastructure in the region. For instance, it has been estimated that the United States’ healthcare consumption expenditure per capita is USD 10,224, and the national health expenditure as a percent of GDP in the United States was 19.7% in 2020. In addition, the growing prevalence of venous diseases or chronic venous insufficiency (CVI) is likely to drive the growth of the market. Furthermore, increasing demand for minimally invasive procedures, the growing geriatric population, and unhealthy lifestyles are increasing the adoption of venous occlusion treatment. According to the Centers for Disease Control and Prevention, 2020, it has been estimated that 900,000 people are affected, and 60,000-100,000 Americans die from deep vein thrombosis in the United States. In addition, approximately 5% to 8% of the US population has one of several inherited genetic risk factors known as inherited thrombophilias, which increases the risk of venous thrombosis.
Chronic Venous Occlusions Treatment Market Competitor Analysis
The chronic venous occlusions treatment market is fairly fragmented in nature, with the presence of a number of players in the market. The companies present in the market are using diverse strategies such as mergers, acquisitions, partnerships, and collaborations to maintain their leading position. Some of the major players in the market include Cardinal Health, Boston Scientific Corporation, Richard Wolf GmbH, and Stryker.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Availability of Advanced Treatments and Devices
4.2.2 Increasing Prevalence of Venous Occlusion Diseases
4.3 Market Restraints
4.3.1 Cost Consciousness and Risks Associated with Treatment
4.3.2 Risks and Complications Associated with Treatment
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 Treatment Type
5.1.1 Chronic Deep Vein Thrombosis
5.1.2 Venous Obstruction
5.1.3 Deep Vein Insufficiency
5.1.4 Other Treatment Types
5.2 Product Type
5.2.1 Devices
5.2.2 Therapeutics
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle-East
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle-East
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Cardinal Health
6.1.2 Stryker
6.1.3 Cook Medical
6.1.4 Boston Scientific Corporation
6.1.5 Edward Lifesciences
6.1.6 Angio Dynamics
6.1.7 ENDOCOR
6.1.8 Rontis
6.1.9 Penumbra
6.1.10 BD Advancing the World of Health
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
